International Precision Child Health Partnership (IPCHiP): an initiative to accelerate discovery and improve outcomes in rare pediatric disease
Top Cited Papers
Open Access
- 27 February 2025
- journal article
- review article
- Published by Springer Nature in npj Genomic Medicine
- Vol. 10 (1) , 1-14
Abstract
Advances in genomic technologies have revolutionized the diagnosis of rare genetic diseases, leading to the emergence of precision therapies. However, there remains significant effort ahead to ensure the promise of precision medicine translates to improved outcomes. Here, we discuss the challenges in advancing precision child health and highlight how international collaborations such as the International Precision Child Health Partnership, which embed research into clinical care, can maximize benefits for children globally.Keywords
This publication has 155 references indexed in Scilit:
- Targeted treatment of migrating partial seizures of infancy with quinidineAnnals of Neurology, 2014
- KCNT1gain of function in 2 epilepsy phenotypes is reversed by quinidineAnnals of Neurology, 2014
- Diagnostic delays in children with early onset epilepsy: Impact, reasons, and opportunities to improve careEpilepsia, 2013
- De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancyNature Genetics, 2012
- Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsyNature Genetics, 2012
- Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndromeBrain, 2012
- The importance of rare diseases: from the gene to societyArchives of Disease in Childhood, 2010
- Developmental Outcome After Epilepsy Surgery in InfancyPediatrics, 2007
- The spectrum of SCN1A-related infantile epileptic encephalopathiesBrain, 2007
- Infantile spasms in Down syndrome—effects of delayed anticonvulsive treatmentEpilepsy Research, 2003